Pipeline

Topical Hemostat
The first flowable hemostat for markets of civilian and military trauama and ENT surgery. Endomedix is currently developing and taking this product through the regulatory process.

Internal Hemostat
Large market, well over $500 million worldwide (Frost & Sullivan). Currently undergoing preclinical trials to position for regulatory submission.

Wound Care
Endomedix technology provides healthcare providers with a cost effective and clinically superior wound care alternative, because of the anti-infective and hemostatic properties of chitosan. Preclinical data supports superior wound healing compared to silvadene.